Stock 2395 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shin Nippon Biomedical Laboratories, Ltd.

Equities

2395

JP3379950003

Biotechnology & Medical Research

Delayed Japan Exchange
Other stock markets
 01:11:39 2024-06-26 EDT 		5-day change 1st Jan Change
1,469 JPY +1.73% Intraday chart for Shin Nippon Biomedical Laboratories, Ltd. +2.94% -13.37%
05-08 Shin Nippon Biomedical Laboratories, Ltd. Announces Fiscal Year End Dividend for the Fiscal Year Ended March 31, 2024, Payable on June 25, 2024; Provides Second Quarter End and Fiscal Year End Dividend Guidance for the Fiscal Year Ended March 31, 2025 CI
05-08 Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Forecasts for the Six Months Ending September 30, 2024 and Year Ending March 31, 2025 CI

Valuation

Fiscal Period: März 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 37,511 21,982 29,101 70,608 114,488 60,117 - -
Enterprise Value (EV) 1 48,320 31,655 34,500 72,748 122,715 78,773 82,891 85,578
P/E ratio 19.2 x 8.62 x 7.95 x 9.91 x 18.9 x 11.4 x 14 x 8.97 x
Yield 0.33% 0.95% 2.86% 2.36% 1.82% 3.29% 3.46% 4.16%
Capitalization / Revenue 2.4 x 1.51 x 1.93 x 3.98 x 4.56 x 2.39 x 1.97 x 1.77 x
EV / Revenue 3.09 x 2.17 x 2.28 x 4.1 x 4.89 x 2.98 x 2.72 x 2.52 x
EV / EBITDA - - - - 18.1 x 13.1 x 14.5 x 9.51 x
EV / FCF 37,749,621 x 21,047,038 x 9,271,647 x 17,121,190 x -76,220,422 x -12,271,792 x -16,199,044 x -452,791,050 x
FCF Yield 0% 0% 0% 0% -0% -0% -0% -0%
Price to Book 1.32 x 1.35 x 1.85 x 3.61 x 4.37 x 1.85 x 1.65 x 1.48 x
Nbr of stocks (in thousands) 41,632 41,632 41,632 41,632 41,632 41,632 - -
Reference price 2 901.0 528.0 699.0 1,696 2,750 1,444 1,444 1,444
Announcement Date 19-05-10 20-05-11 21-05-10 22-05-06 23-05-08 24-05-08 - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: März 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 15,658 14,561 15,110 17,748 25,090 26,450 30,500 34,000
EBITDA 1 - - - - 6,789 6,030 5,700 9,000
EBIT 1 829 2,228 2,529 4,195 5,245 4,162 2,800 6,000
Operating Margin 5.29% 15.3% 16.74% 23.64% 20.9% 15.74% 9.18% 17.65%
Earnings before Tax (EBT) 1 1,650 3,062 4,175 8,183 7,759 6,974 5,800 9,100
Net income 1 1,950 2,550 3,661 7,127 6,060 5,531 4,300 6,700
Net margin 12.45% 17.51% 24.23% 40.16% 24.15% 20.91% 14.1% 19.71%
EPS 2 46.84 61.25 87.95 171.2 145.6 132.9 103.3 160.9
Free Cash Flow 1,280 1,504 3,721 4,249 -1,610 -6,419 -5,117 -189
FCF margin 8.17% 10.33% 24.63% 23.94% -6.42% -24.27% -16.78% -0.56%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) 65.64% 58.98% 101.64% 59.62% - - - -
Dividend per Share 2 3.000 5.000 20.00 40.00 50.00 50.00 50.00 60.00
Announcement Date 19-05-10 20-05-11 21-05-10 22-05-06 23-05-08 24-05-08 - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: März 2020 S1 2021 S1 2022 S1 2022 Q3 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 S1 2025 Q3 2025 Q4 2026 S1
Net sales 1 6,389 7,003 7,961 4,985 4,046 6,302 10,348 6,023 8,718 5,805 6,079 11,884 6,100 8,466 6,705 7,155 13,860 7,205 9,435 -
EBITDA - - - - - - - - - - - - - - - - - - - -
EBIT 1 1,078 1,161 1,969 1,331 714 1,599 2,313 1,470 1,461 1,227 1,122 2,349 186 1,627 -45 445 400 415 1,985 -202
Operating Margin 16.87% 16.58% 24.73% 26.7% 17.65% 25.37% 22.35% 24.41% 16.76% 21.14% 18.46% 19.77% 3.05% 19.21% -0.67% 6.22% 2.89% 5.76% 21.04% -
Earnings before Tax (EBT) 1,252 1,300 3,905 2,139 2,771 3,119 5,890 -259 2,128 1,941 1,872 3,814 1,124 - 605 1,195 1,800 1,365 2,635 -
Net income 1 877 1,139 3,503 1,744 1,944 2,475 4,419 -68 1,708 1,373 1,593 2,966 828 1,737 629 950 1,580 1,136 1,583 -
Net margin 13.73% 16.26% 44% 34.98% 48.05% 39.27% 42.7% -1.13% 19.59% 23.66% 26.2% 24.96% 13.57% 20.52% 9.38% 13.28% 11.4% 15.77% 16.78% -
EPS 21.07 27.36 84.15 41.90 46.70 - 106.2 -1.640 41.04 32.98 38.26 71.24 19.90 - - - - - - -
Dividend per Share - - - - - - 20.00 - - - - 20.00 - - - - - - - -
Announcement Date 19-11-08 20-11-06 21-11-02 22-02-02 22-07-29 22-10-31 22-10-31 23-01-31 23-05-08 23-08-02 23-11-07 23-11-07 24-02-02 24-05-08 - - - - - -
1JPY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: März 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 10,809 9,673 5,399 2,140 8,227 15,575 22,774 25,461
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) - - - - 1.212 x 2.583 x 3.995 x 2.829 x
Free Cash Flow 1,280 1,504 3,721 4,249 -1,610 -6,419 -5,117 -189
ROE (net income / shareholders' equity) 7.1% 11.4% 22.9% 40.4% 26.5% 18.3% 12.2% 17.4%
ROA (Net income/ Total Assets) 2.88% 6.69% 9.6% 18.6% 19% 10.5% 7.2% 10.5%
Assets 1 67,662 38,128 38,154 38,406 31,821 52,647 59,722 63,810
Book Value Per Share 2 682.0 391.0 378.0 470.0 630.0 819.0 873.0 974.0
Cash Flow per Share 79.50 90.80 116.0 199.0 183.0 175.0 - -
Capex 1 1,612 1,514 1,025 1,703 5,614 8,525 10,500 8,000
Capex / Sales 10.3% 10.4% 6.78% 9.6% 22.38% 32.23% 34.43% 23.53%
Announcement Date 19-05-10 20-05-11 21-05-10 22-05-06 23-05-08 24-05-08 - -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Shin Nippon Biomedical Laboratories, Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1,444 JPY
Average target price
2,800 JPY
Spread / Average Target
+93.91%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. Stock Shin Nippon Biomedical Laboratories, Ltd.
-13.37% 376M
MODERNA, INC. Stock Moderna, Inc.
+38.36% 52.73B
LONZA GROUP AG Stock Lonza Group AG
+36.73% 39B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.63% 38.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+25.46% 30.38B
CELLTRION, INC. Stock Celltrion, Inc.
-11.17% 26.39B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.44% 26.08B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+45.09% 14.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.93% 12.6B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-5.30% 11.51B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 2395 Stock
  4. Financials Shin Nippon Biomedical Laboratories, Ltd.